Mesoblast (ASX:MSB) said that it will meet with the US Food and Drug Administration in July to discuss a pivotal trial of Ryoncil, seeking to extend the drug's label from children to adults with steroid-refractory acute graft versus host disease, according to a Thursday Australian bourse filing.
The trial is to be conducted with the National Institutes of Health-funded Bone Marrow Transplant Clinical Trials Network.
The company also advanced an accelerated approval pathway for Revascor in the treatment of patients with ischemic chronic heart failure with reduced ejection fraction and inflammation.
The firm held a type B meeting with the US FDA in early June under its regenerative medicines advanced therapy designation for Revascor to discuss components of a potential filing for a biologics license application.
It achieved alignment with the regulator on items regarding chemistry, manufacturing, and controls, as well as potency assays for commercial product release, and proposed design and primary endpoint for the confirmatory trial post-approval, the filing said.
The firm's shares rose over 3% in recent trading on Thursday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。